Source comparison
CJC-1295 No DAC Ipamorelin Protocol: Dosing Comparison
Standard Research Protocol 100–200mcg 200–300mcg 2–3× daily (6–8hr intervals) 200–300% 92–96% preserved Optimal balance of efficacy and receptor preservation. Replicates physiological pulse architecture without sustained receptor occupancy Low-Dose Maintenance
This comparison does not assign a generated winner or score.
- Standard Research Protocol
- 100–200mcg
- 200–300mcg
- 2–3× daily (6–8hr intervals)
- 200–300%
- 92–96% preserved
- Optimal balance of efficacy and receptor preservation. Replicates physiological pulse architecture without sustained receptor occupancy
- Low-Dose Maintenance
- 50–100mcg
- 100–150mcg
- 2× daily (morning/evening)
- 150–200%
- 96–98% preserved
- Suitable for long-term protocols where baseline GH pulsatility is intact and modest amplification is sufficient
- High-Intensity Research
- 300–500mcg
- 3× daily (fasted/pre-workout/pre-sleep)
- 300–500%
- 88–92% preserved
- Produces maximal GH elevation but approaches the threshold where receptor downregulation becomes measurable. Limited to 8–12 week cycles
- CJC-1295 With DAC (comparison)
- 1000–2000mcg
- 1× weekly + daily ipamorelin
- 250–350% (sustained)
- 68–78% at 12 weeks
- Higher total GH AUC but flattened pulse architecture and measurable receptor desensitization. Not recommended for protocols >12 weeks